Notice of Half Year Results

BioPharma Credit PLC
16 August 2024
 

16 August 2024

BIOPHARMA CREDIT PLC

(the "Company") 

NOTICE OF HALF YEAR RESULTS

BioPharma Credit PLC (LSE: BPCR), the specialist life sciences debt investor, will announce its Half Year Results for the period ending 30 June 2024 on Tuesday 24 September 2024.

A management presentation will be delivered at 14.00 BST through a webcast facility. To register to attend or request details, RSVP to biopharmacredit@buchanan.uk.com.

-Ends-

 Enquiries

 BioPharma Credit PLC

via Link Company Matters Limited

Company Secretary

+44 (0) 333 300 1950 

Buchanan

+44 (0)20 7466 5000

David Rydell / Mark Court / Jamie Hooper / Henry Wilson

biopharmacredit@buchanan.uk.com

 

Notes to Editors:

BioPharma Credit PLC is London's only listed specialist investor in debt from the life sciences industry and joined the LSE on 27 March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings